AR107560A1 - Compuesto que disminuye la glucosa en la sangre - Google Patents

Compuesto que disminuye la glucosa en la sangre

Info

Publication number
AR107560A1
AR107560A1 ARP170100312A ARP170100312A AR107560A1 AR 107560 A1 AR107560 A1 AR 107560A1 AR P170100312 A ARP170100312 A AR P170100312A AR P170100312 A ARP170100312 A AR P170100312A AR 107560 A1 AR107560 A1 AR 107560A1
Authority
AR
Argentina
Prior art keywords
chain
cysteine
compound
blood
disulfide bond
Prior art date
Application number
ARP170100312A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Amunix Operating Inc filed Critical Lilly Co Eli
Publication of AR107560A1 publication Critical patent/AR107560A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

La presente solicitud se refiere al campo de la medicina y al tratamiento de la diabetes o hiperglucemia dentro de ese campo. Reivindicación 1: Un compuesto, caracterizado porque comprende una cadena A y una cadena B, en donde la secuencia de aminoácidos de la cadena A es SEC ID Nº 1 y la secuencia de aminoácidos de la cadena B es SEC ID Nº 2, y en donde las cadenas A y B contienen un enlace de disulfuro entre la cisteína en la posición 7 de la cadena A y la cisteína en la posición 7 de la cadena B, un enlace de disulfuro entre la cisteína en la posición 20 de la cadena A y la cisteína en la posición 19 de la cadena B, y un enlace de disulfuro entre la cisteína en la posición 6 de la cadena A y la cisteína en la posición 11 de la cadena A.
ARP170100312A 2016-02-24 2017-02-08 Compuesto que disminuye la glucosa en la sangre AR107560A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662299131P 2016-02-24 2016-02-24

Publications (1)

Publication Number Publication Date
AR107560A1 true AR107560A1 (es) 2018-05-09

Family

ID=58191654

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100312A AR107560A1 (es) 2016-02-24 2017-02-08 Compuesto que disminuye la glucosa en la sangre

Country Status (6)

Country Link
US (1) US10035839B2 (es)
JP (1) JP6320648B1 (es)
AR (1) AR107560A1 (es)
JO (2) JOP20170040B1 (es)
TW (1) TWI633116B (es)
WO (1) WO2017146979A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102348715B (zh) * 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
KR20230083294A (ko) 2020-09-30 2023-06-09 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩타이드 접합체 및 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102348715B (zh) * 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
AR090843A1 (es) * 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica

Also Published As

Publication number Publication date
TWI633116B (zh) 2018-08-21
US10035839B2 (en) 2018-07-31
US20170240614A1 (en) 2017-08-24
WO2017146979A1 (en) 2017-08-31
JP6320648B1 (ja) 2018-05-09
TW201738265A (zh) 2017-11-01
JOP20210201A1 (ar) 2023-01-30
JOP20170040B1 (ar) 2021-08-17
JP2018513854A (ja) 2018-05-31

Similar Documents

Publication Publication Date Title
AR107560A1 (es) Compuesto que disminuye la glucosa en la sangre
PE20191836A1 (es) Compuesto de insulina acilada
MD3292141T2 (ro) Proteine de fuziune
CY1115649T1 (el) Σκευασματα ινσουλινων μακρας-δρασης
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
CO2019006341A2 (es) Fragmento fab novedoso de anticuerpo anti-muc1 de humano
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
MY193519A (en) Method for decreasing immunogenicity of protein and peptide
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
MX2015014007A (es) Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada.
CL2021002397A1 (es) Derivados de insulina sensibles a la glucosa
EA201992562A1 (ru) Пептиды для лечения сахарного диабета
PE20220570A1 (es) Anticuerpo anti-epha4 humano
CL2017000578A1 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañia
MY189759A (en) Conjugate of finasteride with peptide
BR112021026364A2 (pt) Antígenos de câncer e métodos
DOP2016000096A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
MX2018011121A (es) Prevención de la adherencia de tejido biológico.
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
EA201991185A1 (ru) Композиции для личной гигиены, содержащие цистин
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
AR087811A1 (es) Vacuna contra el staphylococcus aureus

Legal Events

Date Code Title Description
FB Suspension of granting procedure